Greater China News
Gracell Biotechnologies to Participate in Jefferies Healthcare Conference
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, May 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer and autoimmune diseases, today announced that the management team will participate in the Jefferies Healthcare Conference on June 8, 2023, in New York, NY.
BeiGene to Present at Upcoming Investor Conferences
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences.
HuidaGene Therapeutics Appoints Alvin Luk as Chief Executive Officer
SHANGHAI and CLINTON, N.J., May 24, 2023 /PRNewswire/ -- HuidaGene Therapeutics (辉大基因; HuidaGene), a clinical-stage genome-editing company, today announced the appointment of gene therapy industry veteran, Alvin Luk, Ph.D., M.B.A., C.C.R.A., as Co-Founder, Member of the Board of Directors, and Chief Executive Officer.
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema
TAIPEI, May 23, 2023 /PRNewswire/ -- Allgenesis Biotherapeutics Inc., a clinical-stage specialty pharmaceutical company focused on developing novel ophthalmic drugs, announces exciting preliminary data from the two initial cohorts of the on-going AG-77305 FIH Phase 2a clinical trial for the treatment of Diabetic Macular Edema (DME) in the US.
Minghui Pharmaceutical Inc. Announces First-in-Human Dose of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody in Phase 1a Healthy Volunteer Study
SHANGHAI and HANGZHOU, China and WILMINGTON, Del., May 23, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a clinical-stage biopharmaceutical company focusing on oncology and autoimmune diseases, today announced that the phase 1a trial of MHB018A has commenced with the dosing of its first subject. The phase 1a, randomized, double-blinded, vehicle-controlled first-in-human study aims to evaluate the safety, tolerability and pharmacokinetics of MHB018A in healthy volunteers.
Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers
SHANGHAI and HONG KONG, May 23, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, today announced that ATG-022, a Claudin 18.2 antibody drug conjugate (ADC) in-house discovered and developed by Antengene, has been granted two Orphan Drug Designations (ODD) consecutively by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and pancreatic cancer. To date, Antengene has received 3 ODDs from the FDA for two of its in-house products.
Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in China
SHANGHAI, China, May 24, 2023 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, announced that it has established a commercial partnership with Keyuan Xinhai (Beijing) Medical Products Trading Co. Ltd. (Kyuan Trade), a leading pharmaceutical import and distribution company in China, as it prepares for the commercial launch of AdimFlu-S (QIS), the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. Clover expects to launch AdimFlu-S (QIS) in H2 2023.
Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer
SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has accepted the supplemental new drug application ("sNDA”) for the company’s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS ≥ 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (“TNBC”).
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
NEW YORK, May 15, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) announced today that Hefei Tianhui Biotechnology Co. Ltd. (HTIT), a strategic partner of Oramed, has successfully completed its Phase 3 trials of oral insulin in type 2 diabetes in China under a differentiated study protocol. HTIT is now moving toward regulatory approval and has submitted the data to the National Medical Products Administration (NMPA, formerly the CFDA).
Lab monkey prices soar in U.S. after China cuts off exports
Source: KAORI YOSHIDA, Nikkei Asia staff writer “NEW YORK — Prices of laboratory monkeys in the U.S. have jumped around 15-fold from pre-COVID levels, with ... Read more
